14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CBIO vs EYEG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over EYEG (EYEG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CBIO carries a Unified Composite Score of 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin), whereas EYEG carries 55.0/100 (HOLD) at $33.73 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While EYEG currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. CBIO 49.2/100 HOLD), CBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CBIO vs EYEG. Trailing 12-month operating profitability (CBIO -1228.4% vs EYEG N/A) and valuation multiples (CBIO N/M vs EYEG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CBIO vs EYEG Key Questions & Quantitative Answers
As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over EYEG (EYEG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CBIO carries a Unified Composite Score of 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin), whereas EYEG carries 55.0/100 (HOLD) at $33.73 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While EYEG currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. CBIO 49.2/100 HOLD), CBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CBIO leads the Growth & Scale pillar: CBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin), compared with EYEG at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CBIO generates $15M in USD-normalized revenue versus N/A for EYEG. In operating R&D and SG&A reinvestment, CBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EYEG.
CBIO screens cheaper on headline valuation multiples. CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin), whereas EYEG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBIO (-160.8% ROE) versus EYEG (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, CBIO carries 215.9% implied volatility (98th %ile, Extreme (>80th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 60% Vol realized risk). By comparison, EYEG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.13β · 5% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.